Analysts Project Significant Gains for Salesforce and Abbott Laboratories

Despite Salesforce remaining down, an analyst projects over 100% returns for the company, while another analyst sees 35% gains for Abbott Laboratories, which has lost 16% this year. These forecasts suggest potential rebounds for both companies.